switching from semaglutide to tirzepatide between weight-loss medications Switching from semaglutide to tirzepatide

Metabolic dysfunction-associated steatotic liver disease (MASLD, formerly known as NAFLD) affects millions of people worldwide

Semaglutide is a glucagon-like peptide-1 (GLP-1) agonist, available as the brand-name medications Wegovy, Ozempic, and Rybelsus

More detailed body scans in clinical trials show that a fraction of the weight lost (a few percent) is from lean tissue, including muscle

treatment setting, those between female and male rats or unknown other causes remains unclear

If approved, zanidatamab will be the first HER2-targeted treatment specifically indicated for patients with HER2+ locally advanced or metastatic biliary tract cancer

Anecdotal reports and clinical experience from obesity specialists often include notable back pain relief as one of the first changes patients notice within the first few months of GLP-1 therapy